- Home
- INKT vs ABVC Comparison
INKT vs ABVC Comparison
Compare INKT & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ABVC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 58.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | ABVC |
|---|---|---|
| Price | $12.78 | $2.26 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 19.0K | ★ 63.7K |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 56.52 |
| 52 Week Low | $4.56 | $0.40 |
| 52 Week High | $76.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | INKT | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 34.12 |
| Support Level | $11.48 | $2.06 |
| Resistance Level | $12.50 | $2.87 |
| Average True Range (ATR) | 0.91 | 0.18 |
| MACD | 0.29 | -0.04 |
| Stochastic Oscillator | 77.21 | 22.88 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.